SCA
VIR icon

Spearhead Capital Advisors’s Vir Biotechnology VIR Stock Holding History

Spearhead Capital Advisors’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-8,765
Closed -$223K – 170
2022
Q2 		$223K Sell
8,765
-127
-1% -$2.96K 0.03% 159
2022
Q1 		$229K Buy
+8,892
New +$264K 0.03% 174

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Spearhead Capital Advisors's VIR Position: Q3 2022 in Review

Spearhead Capital Advisors sold out of Vir Biotechnology (VIR) in Q3 2022, closing a stake of 8,765 shares — an estimated $223K sold.

Spearhead Capital Advisors first reported a position in VIR in Q1 2022 and held it in 2 quarters. The position peaked at $229K in Q1 2022. 220 funds tracked by Wall St. Rank hold VIR as of Q3 2022.

  • Spearhead Capital Advisors reported no remaining Vir Biotechnology position as of Q3 2022 after selling out during the quarter.
  • Spearhead Capital Advisors sold 8,765 Vir Biotechnology shares in Q3 2022, an estimated $223K.
  • Spearhead Capital Advisors first reported a position in Vir Biotechnology in Q1 2022 and held it in 2 quarters.
  • Spearhead Capital Advisors's Vir Biotechnology position peaked at $229K in Q1 2022.
  • 220 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2022.

Based on Spearhead Capital Advisors's 13F filing for Q3 2022, filed 9 Nov 2022.